Meeting Spolight: 2021 International Kidney Cancer Symposium | Supplement

Managing Adverse Reactions in Patients With RCC Treated With Lenvatinib/Pembrolizumab

December 21, 2021

Clinical Articles

Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.